Lantern Pharma Inc.: management transactions · United States · SEC (Form 4)

About Lantern Pharma Inc.

Lantern Pharma Inc. is a US-based biopharmaceutical company listed on the Nasdaq Stock Market in the United States under the ticker LTRN. Headquartered in Dallas, Texas, the company is focused on precision oncology and on using artificial intelligence to accelerate cancer drug discovery and development. Its principal executive offices are at 1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201. Lantern is positioned as a small-cap, development-stage biotech with a technology-driven business model rather than a traditional commercial pharma franchise. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1763950/000164117225022896/formars.pdf)) The company’s core platform is RADR®, its proprietary AI and machine-learning engine for oncology. Lantern says RADR® leverages roughly 200 billion oncology-focused data points and more than 200 machine-learning algorithms to support target identification, biomarker analysis, patient stratification, and trial design. In practical terms, Lantern’s model combines artificial intelligence, genomics, cloud computing, and automated data analytics to narrow the probability of failure in early drug development and to shorten timelines. This makes Lantern a niche player at the intersection of biotechnology and health-tech, with differentiation based on data science and precision-medicine workflows. ([lanternpharma.com](https://www.lanternpharma.com/about)) Lantern’s pipeline remains centered on oncology and includes multiple investigational programs aimed at different cancer types and patient segments, including lung cancer, breast cancer, lymphoma, sarcoma, pediatric brain cancers, and bladder cancer. Recent company disclosures highlight LP-300, LP-284, and STAR-001 as important assets, with clinical and regulatory progress intended to create value through milestone execution rather than through current product sales. In that sense, Lantern remains a pipeline-and-platform story, with its long-term equity case tied to clinical readouts, regulatory progress, and potential partnerships. ([ir.lanternpharma.com](https://ir.lanternpharma.com/news-1/news/news-details/2026/Lantern-Pharma-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates/default.aspx)) From a competitive standpoint, Lantern operates in a crowded oncology biotech market, but its AI-first approach gives it a distinct narrative versus conventional drug developers. The company is trying to convert proprietary data, model development, and biomarker-driven trial design into a repeatable development advantage. Its positioning is strengthened by the fact that it is not only advancing internal programs but also commercializing adjacent AI tools, including withZeta.ai and predictBBB.ai, which could broaden the opportunity set beyond single-asset drug development. ([ir.lanternpharma.com](https://ir.lanternpharma.com/news-1/news/news-details/2026/Lantern-Pharma-Launches-withZeta-ai--the-Worlds-First-Multi-Agentic-A-I--Co-Scientist-for-Rare-Cancer-Drug-Discovery--Development--Subscriptions-Now-Open-Debut-Events-at-Nasdaq-MarketSite-on-416-and-at-AACR-2026-from-417-to-422/default.aspx?utm_source=openai)) Recent news indicates a clear push to industrialize the platform. In 2026, Lantern launched withZeta.ai as a commercially live multi-agentic AI co-scientist for rare cancer drug discovery and clinical-trial development, expanded predictBBB.ai into a real-time quantitative model, and announced new regulatory progress for LP-284 as well as FDA IND clearance for a planned pediatric CNS cancer trial through Starlight Therapeutics. The company also reiterated in its 2025 annual report and 2026 business updates that its commercial and clinical efforts remain subject to funding, development, and adoption risk, which is typical for an early-stage precision oncology company. ([ir.lanternpharma.com](https://ir.lanternpharma.com/news-1/news/news-details/2026/Lantern-Pharma-Launches-withZeta-ai--the-Worlds-First-Multi-Agentic-A-I--Co-Scientist-for-Rare-Cancer-Drug-Discovery--Development--Subscriptions-Now-Open-Debut-Events-at-Nasdaq-MarketSite-on-416-and-at-AACR-2026-from-417-to-422/default.aspx?utm_source=openai))